Larimar Therapeutics, Inc. LRMR
3.14 USD -0.08 (-2.48%)
Regular-session close
2.88 -0.26 -8.36%
After hours · Nov 20, 5:47 PM ET
2.96 Day range 3.22
1.92 52-week range 6.42
- YTD
- -17.59%
- 1 year
- -6.82%
5D -0.06 (-1.87%)
- Market cap
- 328.55M
- EPS (ttm)
- -1.67
- Shares out
- 63.81M
- Forward P/E
- -2.57
- YTD return
- -17.59%
- 1-year return
- -6.82%
- 50-day average
- 6.92
- 200-day average
- 7.61
- Enterprise value
- 57.52M
- Volume
- 1.71M
- Avg volume
- 1.36M
- Open
- 3.15
- Previous close
- 3.22
- Day's range
- 2.96 – 3.22
- 52-week range
- 1.92 – 6.42
- Beta
- 0.71
- Analysts
- Strong Buy
- Price target
- 20.41 (+549.9%)
Key statistics
- Price / book
- 1.27
- Free cash flow
- -35.22M
- Total cash
- 203.71M
- Total debt
- 5.36M
- Return on equity
- -44.50%
- Short % of float
- 9.31%
Fundamental scorecard
4 of 25 checks passed on LRMR’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
LRMR Revenue — quarterly 0
LRMR Net income — quarterly -31.14M
LRMR EPS — quarterly -0.29
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.37 | -0.24 | +0.13 | +35.14% |
| Aug 7, 2024 | Jun 1, 2024 | -0.32 | -0.34 | -0.02 | -6.25% |
| May 9, 2024 | Mar 1, 2024 | -0.24 | -0.27 | -0.03 | -12.50% |
| Mar 14, 2024 | Dec 1, 2023 | -0.25 | -0.30 | -0.05 | -20.00% |
| Nov 14, 2023 | Sep 1, 2023 | -0.23 | -0.21 | +0.02 | +8.70% |
| Aug 10, 2023 | Jun 1, 2023 | -0.21 | -0.19 | +0.02 | +9.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2024 | Oppenheimer | init | — | Outperform |
| Oct 3, 2024 | Wedbush | init | — | Outperform |
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- larimartx.com
News
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $9
Larimar Therapeutics Q3 EPS $(0.29) Beats $(0.35) Estimate
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update Larimar Therapeutics Completes Rolling BLA Submission To FDA Seeking Accelerated Approval Of Nomlabofusp For Treatment Of Patients With Friedreich’s Ataxia
Your note
Sign in to keep a note on LRMR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN MAIMON CAROLE S | Chief Executive Officer | Stock Award(Grant) | Jan 16, 2024 | 332,954 |
| CELANO MICHAEL | Chief Financial Officer | Stock Award(Grant) | Jan 16, 2024 | 143,996 |
| CLAYTON RUSSELL | Officer | Stock Award(Grant) | Jan 16, 2024 | 22,500 |
| FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 15, 2024 | 0 |
| HAMILTON THOMAS EDWARD | Director | Purchase | Feb 15, 2024 | 724,231 |
| SHANKAR GOPI | Officer | Stock Award(Grant) | Jan 16, 2024 | 27,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 33.28% | 21,231,974 | 84.08M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.47% | 6,045,351 | 23.94M | Sep 29, 2024 |
| Janus Henderson Group PLC | 8.72% | 5,566,855 | 22.04M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 6.66% | 4,249,491 | 16.83M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 6.53% | 4,166,829 | 16.50M | Sep 29, 2024 |
| Blackrock Inc. | 4.66% | 2,972,953 | 11.77M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.10% | 1,341,890 | 5.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.72% | 1,095,985 | 4.34M | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.82% | 524,800 | 2.08M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 510,244 | 2.02M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.68% | 431,074 | 1.71M | Aug 30, 2024 |
| Alger Fund-Small Cap Growth Fund | 0.63% | 398,960 | 1.58M | Jul 30, 2024 |
